Kaplan-Meier survival curves showed that menstrual status, N staging, T staging, TNM staging, and pCR status affected the prognosis of HER2-low breast cancer patients (<i>p</i> < 0.05).<h4>Conclusion</h4>HER2-low breast cancer exhibits distinct biological behaviors, suggesting personalized treatment approaches. The gene discussed is ERBB2; the disease is breast cancer.